Introduction: ADA guidelines recommend costly cardioprotective medications as second-line therapy for patients with diabetes and prevalent cardiovascular disease (CVD). High sensitivity cardiac troponin T (hs-cTnT) and I (hs-cTnI) may identify those at high risk in the absence of CVD and inform prioritization for treatment with newer classes of medications.

Methods: We conducted a prospective cohort analysis of middle-age adults (mean age 63, 52% female, 30% black) in the Atherosclerosis Risk in Communities (ARIC) Study with diabetes (1996-1998, n=1,415). Participants were followed >20 years for heart failure (HF), coronary heart disease, and death. We used Cox models to evaluate the risk associated with independent and joint elevations (>90th percentiles) in hs-cTnT and hs-cTnI.

Results: Elevations in hs-cTnT (26%) or I (19%) were common, with 10% of those without CVD having elevations in both. Elevated hs-cTnT and hs-cTnI were independently associated with all three outcomes (and jointly improved C-statistics). For HF and death, those with elevations in both troponins in the absence of CVD showed similar risk as those with prevalent CVD (Table).

Conclusions: Hs-cTnT and I are independently prognostic of cardiovascular risk and mortality among adults with diabetes. These biomarkers may help identify patients for novel cardioprotective anti-hyperglycemics, even in the absence of pre-existing CVD.

O. Tang: None. K. Matsushita: Consultant; Self; Akebia, Kyowa Hakko Kirin Co., Ltd. Research Support; Self; Fukuda Denshi, Kyowa Hakko Kirin Co., Ltd. J. Coresh: None. B. Mcevoy: None. A. Sharrett: None. C.M. Ballantyne: Consultant; Self; Abbott, Akcea Therapeutics, Amarin Corporation, Amgen Inc., AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Esperion, Gilead Sciences, Inc., Matinas BioPharma, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Novo Nordisk Inc., Regeneron Pharmaceuticals, Roche Diagnostic USA, Sanofi. Research Support; Self; Abbott, Akcea Therapeutics, Amarin Corporation, Amgen Inc., Esperion, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Roche Diagnostic USA, Sanofi. Other Relationship; Self; Roche Diagnostic USA. R.C. Hoogeveen: Consultant; Self; Denka Seiken. Research Support; Self; Abbott, American Heart Association, National Heart, Lung, and Blood Institute, SomaLogic, Inc. E. Selvin: None.


National Institutes of Health

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at